Avoidance and Cautious Use of Mast Cell‑Activating Medications in MCAS

Direct Mast Cell Degranulators

Opioids such as morphine and codeine should be avoided in patients with mast cell activation syndrome because they directly trigger mast cell degranulation, increasing the risk of severe mediator release. 1
Non‑steroidal anti‑inflammatory drugs (NSAIDs) can provoke mast cell degranulation; aspirin may be used only in a tightly controlled setting to inhibit PGD₂ synthesis for refractory flushing, but it carries a high risk of triggering degranulation. 2
Neuromuscular blocking agents used during anesthesia are recognized mast cell triggers and should be employed only with extreme caution in MCAS patients. 1
Radiocontrast media are associated with significant mast cell activation; when contrast is unavoidable, a pre‑medication regimen of 50 mg prednisone administered at 13 h, 7 h, and 1 h before the procedure is recommended. 3

Vancomycin has been identified as a direct mast cell degranulator and should be avoided when alternative agents are available for MCAS patients. 2
Fluoroquinolone antibiotics can trigger mast cell activation and are best substituted with other antimicrobial classes in individuals with MCAS. 2
When antibiotics are required, selection of agents without known mast cell‑activating properties is advised. 1

First‑generation H₁ antihistamines (e.g., diphenhydramine, hydroxyzine, chlorpheniramine) possess anticholinergic effects that may lead to cognitive decline, particularly in older adults, and should be used cautiously. 2
These agents may also increase the risk of cardiovascular events in MCAS patients who are already predisposed to such complications. 3
Prefer second‑generation nonsedating H₁ antihistamines (e.g., fexofenadine, cetirizine) over first‑generation drugs whenever possible. 1

For patients with a history of mast cell activation during procedures, pre‑medication with 50 mg prednisone at 13 h, 7 h, and 1 h before the intervention is recommended to reduce the risk of mediator release. 3
All known mast cell‑degranulating agents should be avoided during anesthesia to prevent intra‑operative anaphylactoid reactions. 2
Epinephrine, H₁‑ and H₂‑blocking agents should be immediately available as rescue medications during any invasive procedure. 1

Begin any new drug at the lowest feasible dose and titrate upward only if tolerated, to minimize the chance of triggering mast cell degranulation. 3
Introduce new medications one at a time, allowing sufficient observation periods to identify any specific trigger. 3
Maintain ready access to rescue medications (e.g., epinephrine, antihistamines) whenever a high‑risk drug is initiated. 3
Consider pre‑medication with antihistamines for drugs known to have a high potential for mast cell activation. [1][2]